Baricitinib (LY3009104, INCB028050, LY-3009104, INCB-028050)，又称巴瑞克替尼，是一种选择性、ATP竞争性、可口服的JAK1/2抑制剂，IC₅₀值为5.9 nM和5.7 nM，对JAK3和Tyk2抑制活性较低，对c-Met和Chk2没有抑制作用。Baricitinib常用于治疗成人中中度至重度的活动性类风湿关节炎。

参考文献

[1].Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184 (9):5298-307.

[2].Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015;2 (4):351-5.

[3].Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond) . 2015;39 (11):1607-18.

冰袋运输。粉末直接保存于-25~-15℃，有效期2年。建议干燥避光保存，避免反复冻融。